The landmark RUBY study [56] demonstrated that elevated urinary CCL-14 levels predict persistent and severe AKI (defined as KDIGO stage 3) with superior discriminative performance compared with other contemporary biomarkers. The gene discussed is CCL14; the disease is acute kidney injury.